Brian A. Willis

Brian A. Willis

Auto-generated profile, based on publicly available information

Brian A. Willis

Eisai Inc. Nutley New Jersey USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
AWAlette M. Wessels
Alette M. Wessels
PTPierre N. Tariot
Pierre N. Tariot
JZJennifer A. Zimmer
Jennifer A. Zimmer
KSKatherine J. Selzler
Katherine J. Selzler
SBSonja M. Bragg
Sonja M. Bragg
JSJohn R. Sims
John R. Sims
Alzheimer disease (AD) is manifested by cognitive deterioration and progressive impairment of activities of daily living.1 The pathologic features of AD are characterized by the formation of amyloid plaques and neurofibrillary tangles.2 Quiz Ref ID Cleavage of amyloid precursor protein (APP) by proteases known as secretases (β and γ) gives rise to the group of peptide fragments known as Aβ, the main components of amyloid plaques. Imbalance between production and clearance of Aβ leads to formation of Aβ plaques during early pathogenesis of the disease. Beta-site APP-cleaving enzyme 1 (BACE1/β-secretase) is a type 1 transmembrane aspartic acid protease that cleaves APP at the β-secretase site, after which APP is cleaved by γ-secretase to generate Aβ peptides.3,4 Lanabecestat is a brain-permeable inhibitor of human BACE1 (nonselective for BACE1 vs BACE2) that has been shown to reduce levels of Aβ1-40 and Aβ1-42 in the brain, cerebrospinal fluid (CSF), and plasma in several animal models, as well as in human CSF and plasma.5-7 Based on previous phase 1 data, it was estimated that the mean reduction in CSF Aβ1-42 for the selected dose arms in both studies, lanabecestat, 20 mg, and lanabecestat, 50 mg, was approximately 55% and 75%, respectively.5

21 January 2015 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
PMPatrick C. May
Patrick C. May
BWBrian A. Willis
Brian A. Willis
SLStephen L. Lowe
Stephen L. Lowe
RDRobert A. Dean
Robert A. Dean
SMScott A. Monk
Scott A. Monk
DMDustin J. Mergott
Dustin J. Mergott
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry. Herein, we report the nonclinical and early clinical development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clinical trials in AD. LY2886721 has high selectivity against key off-target proteases, which efficiently translatesin vitroactivity into robustin vivoamyloid β lowering in nonclinical animal models. Similar potent and persistent amyloid β lowering was observed in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects. Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.

18 December 2012 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PTPaula T. Trzepacz
Paula T. Trzepacz
PYPeng Yu
Peng Yu
PBPhani K. Bhamidipati
Phani K. Bhamidipati
BWBrian Willis
Brian Willis
TFTammy Forrester
Tammy Forrester
AIAlzheimer'S Disease Neuroimaging Initiative
Alzheimer'S Disease Neuroimaging Initiative

9 March 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
IGIvelina Gueorguieva
Ivelina Gueorguieva
BWBrian A. Willis
Brian A. Willis
LCLaiyi Chua
Laiyi Chua
KCKay Chow
Kay Chow
CEC. Steven Ernest
C. Steven Ernest
JSJohn R. Sims
John R. Sims
Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II TRAILBLAZER‐ALZ study (NCT03367403). The objectives of the current analyses are to characterize (i) the population pharmacokinetics of donanemab, (ii) the relationship between donanemab exposure and amyloid plaque reduction (response), and (iii) the relationship between donanemab exposure and amyloid‐related imaging abnormalities with edema or effusions (ARIA‐E). Model development included data from participants with mild cognitive impairment or mild to moderate dementia due to AD from the phase Ib study on donanemab (NCT02624778) and participants with early symptomatic AD from the TRAILBLAZER‐ALZ study. The analysis showed donanemab has a terminal elimination half‐life of 11.8 days. Body weight and antidrug antibody titer impact donanemab exposure but not the pharmacodynamic response. Maintaining a donanemab serum concentration above 4.43 μg/mL (95% confidence interval: 0.956, 10.4) is associated with amyloid plaque reduction. The time to achieve amyloid plaque clearance (amyloid plaque level < 24.1 Centiloids) varied depending on the baseline amyloid level, where higher baseline levels were associated with fewer participants achieving amyloid clearance. The majority of participants achieved amyloid clearance by 52 weeks on treatment. Apolipoprotein ε4 carriers, irrespective of donanemab serum exposure, were 4 times more likely than noncarriers to have an ARIA‐E event by 24 weeks.

1 May 2013 in International Psychogeriatrics
Verified
Journal Article
Open access
PDF file
PTPaula T. Trzepacz
Paula T. Trzepacz
JCJeffrey Cummings
Jeffrey Cummings
TKThomas Konechnik
Thomas Konechnik
TFTammy D. Forrester
Tammy D. Forrester
CCCurtis Chang
Curtis Chang
CLConstantine Lyketsos
Constantine Lyketsos
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer's disease (AD). Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory (NPI-4-A/A) derived from the Neuropsychiatric Inventory. Secondary measures included the Cohen-Mansfield Agitation Inventory, Cornell Scale for Depression in Dementia, Frontal Systems Behavior Inventory (FrSBe), and Alzheimer's Disease Assessment Scale-Cognitive. Efficacy was analyzed using mixed-effects model repeated measures from baseline to endpoint. Adverse events (AEs), labs, vital signs, and electrocardiograms were monitored. Results: Baseline characteristics were comparable between groups. Both groups improved on the NPI-4-A/A, but without group differences. Among secondaries, mibampator was significantly better (p = 0.007) than placebo only on the FrSBe. AEs were similar between groups. One death occurred in the placebo group. Conclusion: Possible explanations for no significant group differences include caregiver, drug target engagement, and design issues. This trial is registered on ClinicalTrials.gov; ID: NCT00843518.

1 July 2013 in The American Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PTPaula T. Trzepacz
Paula T. Trzepacz
ASAndrew J Saykin
Andrew J Saykin
PYPeng Yu
Peng Yu
PBPhani Bhamditipati
Phani Bhamditipati
JSJia Sun
Jia Sun
JCJeffrey L. Cummings
Jeffrey L. Cummings